Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
Tóm tắt
Background: To analyze the feasibility of capecitabine with weekly irinotecan and concurrent radiotherapy followed by laparoscopic-total mesorectal excision (LTME) in rectal cancer patients. Methods: Eligible criteria included adenocarcinoma of the rectum staged by endoscopic ultrasonography (u), spiral abdominal and pelvic CT and chest X-ray. Patients received weekly irinotecan 50 mg/m2 (days 1, 8, 15, 22, 29) and capecitabine (days 1 through 5 for 5 weeks); dose level; (DL) I 250 mg/m2/bid; DL II 375 mg/m2/bid; DL III 500 mg/m2/bid, according to phase I methodology. External beam radiotherapy was delivered up to a total dose of 45 Gy in daily fractions of 1.8 Gy, 5 days a week. LTME was planned 5–7 weeks after CRT. Results: From February 2003 to February 2006, 22 patients were included. Median age was 62 (range 48 to 78). Seven pts were uT3N0 and 15 pts uT3N1. Seven patients were treated at DL I, six at DL II and nine at DL III. Grade 3 adverse events were observed in all levels. The maximum tolerated dose was reached at 375 mg/m2 (DL II). Conversion rate to open surgery was 5%. Median hospital stay was 6.6 days. One month post-surgical complications were noted in five patients (23%). Median excised nodes were 11 (range 4–21). Pathological complete response was observed in two patients (9%). Conclusions: LTME after preoperative CRT with CAPIRI is feasible but severe adverse events were found in all levels despite the use of lower dose of capecitabine than previously published.
Tài liệu tham khảo
Kapiteijn E, Marijnen CAM, Nagtegaal I et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646. doi:10.1056/NEJMoa010580
Sauer R, Becker H, Hohenberger W et al (2004) German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740. doi:10.1056/NEJMoa040694
Bosset J-F, Collette L, Calais G et al (2006) Chemotherapy with radiotherapy in rectal cancer. N Engl J Med 355:1114–1123. doi:10.1056/NEJMoa060829
Leroy J, Jamali F, Forbes L et al (2004) Laparoscopic total mesorectal excision (TME) for rectal cancer. Surg Endosc 18:281–289. doi:10.1007/s00464-002-8877-8
Wu X-W, Sun Y-M, Hua Y-B, Shen L-Z (2004) Laparoscopic versus conventional open resection of rectal carcinoma: a clinical comparative study. World J Gastroenterol 10:1167–1170
Rich TA, Skibber JM, Ajani JA et al (1995) Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32:1025–1029. doi:10.1016/0360-3016(95)00020-Y
Dunst J, Reese T, Sutter T et al (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983–3991. doi:10.1200/JCO.2002.02.049
Chen AY, Choy H, Rothenberg ML (1999) DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology 10:39–46
Klautke G, Feyerherd P, Ludwig K et al (2005) Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 92:1215–1220. doi:10.1038/sj.bjc.6602492
Navarro M, Dotor E, Rivera F et al (2006) A phase II study of irinotecan (CPT-11) and 5-fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients (pts) with locally advanced resectable rectal cancer. Int J Radiat Oncol Biol Phys 66:201–205. doi:10.1016/j.ijrobp.2006.04.007
Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, Visa J (2002) Laparoscopic-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer. Lancet 359:2224–2229. doi:10.1016/S0140-6736(02)09290-5
Delgado S, Momblan D, Salvador L et al (2004) Laparoscopic-assisted approach in rectal cancer. Lessons learned from >200 patients. Surg Endosc 18:1457–1462. doi:10.1007/s00464-003-8831-4
Quirke P, Durdey P, Dixon MF et al (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumor spread and surgical excision. Lancet 2:996–999. doi:10.1016/S0140-6736(86)92612-7
Hofheinz RD, Gerstenberg B, Wenz F et al (2005) Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350–1357. doi:10.1200/JCO.2005.04.171
Klautke G, Küchenmeister U, Foitzik T et al (2006) Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 94:976–981. doi:10.1038/sj.bjc.6603053
Willeke F, Horisberger K, Kraus-Tiefenbacher U et al (2007) A phase II trial of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Caplri) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 96:912–917. doi:10.1038/sj.bjc.6603645
Glynes-Jones R, Sebag-Montefiore D, Maughan TS et al (2006) A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic irradiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17:50–56. doi:10.1093/annonc/mdj031
Machiels JP, Duck L, Honhon B et al (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadioOxCape study. Ann Oncol 16:1898–1905. doi:10.1093/annonc/mdi406
Rodel C, Liersch T, Hermann EM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:110–117. doi:10.1200/JCO.2006.08.3675
Rutten H, Sebag-Montefiore D, Glyne-Jones R et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol 24:153s, 2006 (suppl; abstr 3528)
Morino M, Parini U, Giraudo G et al (2003) Laparoscopic total mesorectal excision in a consecutive series of 100 patients. Ann Surg 237:335–342. doi:10.1097/00000658-200303000-00006
Kim JC, Kim TW, Kim JH et al (2005) Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 63:346–353. doi:10.1016/j.ijrobp.2005.02.046
Krishnan S, Janjan N, Skibber J et al (2006) Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66:762–771. doi:10.1016/j.ijrobp.2006.05.063
De Paoli A, Chiara S, Luppi G et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17:246–251 . doi:10.1093/annonc/mdj041
Salerno G, Daniels IR, Moran BJ et al (2006) Clarifying margins in the multidisciplinary management of rectal cancer: the MERCURY experience. Clin Radiol 61:916–923 . doi:10.1016/j.crad.2006.06.005
Pachlivanides G, Gouvas N, Tsiaoussis J et al (2007) Lymph node clearance after total mesorectal excision for rectal cancer: laparoscopic versus open approach. Dig Dis 25:94–99. doi:10.1159/000099176
Wong SJ, Winter K, Meropol NJ et al RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Proc ASCO 2008; 4021
Chau I, Brown G, Cunningham D et al (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668–674. doi:10.1200/JCO.2005.04.4875
Machiels JP, Sempoux C, Scalliet P et al (2007) Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18:738–744. doi:10.1093/annonc/mdl460
Rodel C, Arnold D, Hipp M et al (2008) Phase I–II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70:1081–1086. doi:10.1016/j.ijrobp.2007.07.2356
Czito BG, Bendell JC, Willett CG et al (2007) Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 68:472–478. doi:10.1016/j.ijrobp.2007.02.001
Hofheinz RD, Horisberger K, Woernle C et al (2006) Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66:1384–1390. doi:10.1016/j.ijrobp.2006.07.005